Global Rosuvastatin Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rosuvastatin Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rosuvastatin is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. It belongs to a group of drugs known as "statins." It works by reducing the amount of cholesterol made by the liver. Lowering "bad" cholesterol and triglycerides and raising "good" cholesterol decreases the risk of heart disease and helps to prevent strokes and heart attacks.
Rosuvastatin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rosuvastatin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hyperlipidemia And Mixed Dyslipidemia and Familial Hypercholesterolemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rosuvastatin Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rosuvastatin Drugs key manufacturers include AstraZeneca, Watson, ANGITA and Sun Pharmaceutical Industries, etc. AstraZeneca, Watson, ANGITA are top 3 players and held % sales share in total in 2022.
Rosuvastatin Drugs can be divided into 5 mg Tablet, 10 mg Tablet, 20 mg Tablet and 40 mg Tablet, etc. 5 mg Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Rosuvastatin Drugs is widely used in various fields, such as Hyperlipidemia And Mixed Dyslipidemia, Familial Hypercholesterolemia, Hypertriglyceridemia and Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), etc. Hyperlipidemia And Mixed Dyslipidemia provides greatest supports to the Rosuvastatin Drugs industry development. In 2022, global % sales of Rosuvastatin Drugs went into Hyperlipidemia And Mixed Dyslipidemia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Watson
ANGITA
Sun Pharmaceutical Industries
Segment by Type
5 mg Tablet
10 mg Tablet
20 mg Tablet
40 mg Tablet
Hyperlipidemia And Mixed Dyslipidemia
Familial Hypercholesterolemia
Hypertriglyceridemia
Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
Atherosclerosis
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rosuvastatin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rosuvastatin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rosuvastatin Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Rosuvastatin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rosuvastatin Drugs introduction, etc. Rosuvastatin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rosuvastatin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Rosuvastatin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rosuvastatin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hyperlipidemia And Mixed Dyslipidemia and Familial Hypercholesterolemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rosuvastatin Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rosuvastatin Drugs key manufacturers include AstraZeneca, Watson, ANGITA and Sun Pharmaceutical Industries, etc. AstraZeneca, Watson, ANGITA are top 3 players and held % sales share in total in 2022.
Rosuvastatin Drugs can be divided into 5 mg Tablet, 10 mg Tablet, 20 mg Tablet and 40 mg Tablet, etc. 5 mg Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Rosuvastatin Drugs is widely used in various fields, such as Hyperlipidemia And Mixed Dyslipidemia, Familial Hypercholesterolemia, Hypertriglyceridemia and Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), etc. Hyperlipidemia And Mixed Dyslipidemia provides greatest supports to the Rosuvastatin Drugs industry development. In 2022, global % sales of Rosuvastatin Drugs went into Hyperlipidemia And Mixed Dyslipidemia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Watson
ANGITA
Sun Pharmaceutical Industries
Segment by Type
5 mg Tablet
10 mg Tablet
20 mg Tablet
40 mg Tablet
Segment by Application
Hyperlipidemia And Mixed Dyslipidemia
Familial Hypercholesterolemia
Hypertriglyceridemia
Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
Atherosclerosis
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rosuvastatin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rosuvastatin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rosuvastatin Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Rosuvastatin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rosuvastatin Drugs introduction, etc. Rosuvastatin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rosuvastatin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices